Drug industry leaders faced off with US legislators at a Senate Finance Committee hearing on drug prices Feb. 26, but the tone was more collaborative than confrontational. Industry has reason to be cautiously optimistic after seven of its big pharma leaders got through more than three hours of testimony on drug pricing with relative ease.
Big Pharma Defuses Drug Pricing Landmines On Capitol Hill
Industry's top leaders weren't exactly eager to testify on Capitol Hill. Now they might be wondering why they waited so long. Seven pharma leaders avoided missteps during a Senate Finance Committee hearing on drug pricing Feb. 26.
